The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2
Open accessAbstract
This study investigates the apoptotic activity of the cyclooxygenase-2 (COX-2) inhibitor celecoxib in prostate carcinoma cells. COX-2 is constitutively expressed in androgen-responsive LNCaP and androgen-nonresponsive PC-3 cells. Exposure of these cells to celecoxib induces characteristic features of apoptosis, including morphological changes, DNA laddering, and caspase-3 activation, whereas piroxicam, a COX-1-specific inhibitor, displays no appreciable effect on either cancer cell line even after prolonged exposure. Moreover, the potency of celecoxib in apoptosis induction is significantly higher than that of other COX-2 inhibitors examined despite the observation that these inhibitors exhibit similar IC(50) in COX-2 inhibition. It is noteworthy that normal human prostate epithelial cells, expressing a marginally detectable level of COX-2, are insensitive to the induction of apoptosis by celecoxib. These data suggest a correlation between COX-2 expression and sensitivity to the apoptotic effect of the COX-2 inhibitor. In an effort to delineate the underlying mechanism, we examined the effect of celecoxib on the expression of Bcl-2 as well as the activation of the key anti-apoptotic kinase Akt. In contrast to an earlier report that attributed the apoptotic activity of NS398 in LNCaP cells to Bcl-2 down-regulation, we provide evidence that the induction of apoptosis by celecoxib in LNCaP and PC-3 cells is independent of Bcl-2. First, treatment with celecoxib does not alter the cellular Bcl-2 level in both cell lines. Second, enforced Bcl-2 expression in PC-3 cells does not confer protection against the induction of apoptosis by celecoxib. Our data show that celecoxib treatment blocks the phosphorylation of Akt. This correlation is supported by studies showing that overexpression of constitutively active Akt protects PC-3 cells from celecoxib-induced apoptosis. Nevertheless, how celecoxib down-regulates Akt is not clear because the drug does not adversely affect phosphoinositide 3-kinase activity in vivo and okadaic acid, a protein phosphatase 2A inhibitor, cannot rescue the inhibition. In summary, our data demonstrate that inhibition of Akt activation may play a crucial role in the induction of apoptosis by celecoxib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,978
Cited by
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00183-x · Cited by 1,620
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Cyclo-Oxygenase 2 Function Is Essential for Bone Fracture Healing
Simon, A. M., Manigrasso, M. B., & O'Connor, J. P. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.963 · Cited by 530
Apoptosis as a Novel Target for Cancer Chemoprevention
Sun, S.-Y., Hail, N., & Lotan, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh123 · Cited by 502
Grösch, S., Tegeder, I., Niederberger, E., Bräutigam, L., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0299fje · Cited by 501
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer
Cao, Y., & Prescott, S. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10068 · Cited by 464
Medicinal mushroom modulators of molecular targets as cancer therapeutics
Zaidman, B.-Z., Yassin, M., Mahajna, J., & Wasser, S. P. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-004-1787-z · Cited by 434
Chun, K.-S., & Surh, Y.-J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.031 · Cited by 402
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
Gately, S., & Li, W. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.040 · Cited by 398
Cyclooxygenases in cancer: progress and perspective
Zha, S., Yegnasubramanian, V., Nelson, W. G., Isaacs, W. B., & De Marzo, A. M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.014 · Cited by 389
Tumor-Associated Macrophages: The Double-Edged Sword in Cancer Progression
Chen, J. J. W., Lin, Y.-C., Yao, P.-L., Yuan, A., Chen, H.-Y., Shun, C.-T., Tsai, M.-F., Chen, C.-H., & Yang, P.-C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.172 · Cited by 374
Self-citationThe Contributions of Cyclooxygenase-2 to Tumor Angiogenesis
Gately, S. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026575610124 · Cited by 359
COX-2 as a target for cancer chemotherapy
Ghosh, N., Chaki, R., Mandal, V., & Mandal, S. C. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70262-0 · Cited by 344
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080097 · Cited by 322
Photochemoprevention of ultraviolet B signaling and photocarcinogenesis
Afaq, F., Adhami, V. M., & Mukhtar, H. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.07.019 · Cited by 310
Arico, S., Pattingre, S., Bauvy, C., Gane, P., Barbat, A., Codogno, P., & Ogier-Denis, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201119200 · Cited by 303
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Morgan, T., Koreckij, T., & Corey, E. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787580999 · Cited by 283
Hawk, E. T., & Levin, B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.097 · Cited by 278
Exercise-induced cardioprotection against myocardial ischemia–reperfusion injury
Powers, S. K., Quindry, J. C., & Kavazis, A. N. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.02.006 · Cited by 272
Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
Liu, X., Yue, P., Zhou, Z., Khuri, F. R., & Sun, S.-Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh322 · Cited by 265
Leng, J., Han, C., Demetris, J. A., Michalopoulos, G. K., & Wu, T. (2003) · Hepatology · doi:10.1053/jhep.2003.50380 · Cited by 258
Bolli, R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00414-5 · Cited by 258
Zhu, J., Huang, J.-W., Tseng, P.-H., Yang, Y.-T., Fowble, J., Shiau, C.-W., Shaw, Y.-J., Kulp, S. K., & Chen, C.-S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4063 · Cited by 258
Self-citationChun, K.-H., Kosmeder, J. W., Sun, S., Pezzuto, J. M., Lotan, R., Hong, W. K., & Lee, H.-Y. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.291 · Cited by 255
Choudhari, S. R., Khan, M. A., Harris, G., Picker, D., Jacob, G. S., Block, T., & Shailubhai, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0561 · Cited by 90
Activated PI3K/Akt/COX-2 Pathway Induces Resistance to Radiation in Human Cervical Cancer HeLa Cells
Xia, S., Zhao, Y., Yu, S., & Zhang, M. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0707 · Cited by 78
Metadata
- Authors
- Hsu, A.-L., Ching, T.-T., Wang, D.-S., Song, X., Rangnekar, V. M., & Chen, C.-S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-04
- Volume
- 275
- Issue
- 15
- Pages
- 11397-11403
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1998394615
- Cited by
- 671
- References
- 42
- FWCI
- 31.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.